Dendritic Cell mRNA Vaccines
Dendritic cell mRNA vaccines have shown efficacy in many preclinical and clinical studies. This type of mRNA vaccine is based on the dendritic cells (DCs). As the most efficient and professional antigen-presenting cells (APCs), DCs are capable of presenting antigens processed from various sources to other types of immune cells, to induce novel or enhance existing immune responses. Since ex vivo -loaded DC vaccines induce a predominantly cell-mediated immune response, they are a heavily pursued cancer treatment method. Creative Biogene is a leading mRNA-based drug R&D service provider worldwide. We offer multiple mRNA vaccines, such as dendritic cell mRNA vaccines. Our team of professional scientists can support the design, production and evaluation of dendritic cell mRNA vaccines, meeting our customers' requirements for high-quality products and short production time. Besides, our service is target-oriented with flexible and integrated solutions.
The development of dendritic cell mRNA vaccines
In 1996, dendritic cell mRNA vaccines (DCs electroporated with mRNA) that elicit immune responses against tumor antigens were first reported. From then on, an increasing number of DC-based mRNA vaccine studies started preclinically and clinically for infectious diseases and cancers.
As the most potent APCs of the immune system, DCs are highly amenable to mRNA transfection. Therefore, they present attractive targets for transfection by mRNA vaccines, both in vivo and ex vivo. The antigen-presenting manner of DCs is mainly comprised of two ways. One way is to initiate the adaptive immune response, DCs internalize and proteolytically process antigens, followed by presenting the antigens to CD8+ and CD4+ T cells on major histocompatibility complexes (MHCs, namely, MHC I and MHC II). Another way is by presenting intact antigen to B cells to provoke an antibody response.
To deliver mRNA into DCs, electroporation is an efficient strategy and is frequently used to generate DC-based mRNA vaccines. The principle of this method is to disrupt the cell membrane by an electric shock. With the optimization of multiple electrical parameters, the biological properties of mRNA-loaded DCs, including cell phenotypes and antigen presentation function, can be maintained. Other than electroporation, using lipid-derived carriers is another method to deliver mRNA into DCs to prepare DC-based mRNA vaccines.
Target-oriented and flexible mRNA dendritic cell mRNA vaccine platform
Based on a team of professional scientists and advanced instruments, we can provide the design and production of mRNA-based dendritic cell vaccines. For preparing mRNA-treated DCs, the DCs are extracted from the blood. Then, the DCs are transfected with mRNAs encoding the antigens of interest for further stimulation and maturation. To effectively deliver mRNAs into DCs, we offer the choice of electroporation and lipid-derived carriers. After validating both phenotypes and functions, the mRNA-transfected DCs are given back to the body to stimulate an immune reaction. Finally, we can evaluate DC-based mRNA vaccines using our small animal models.
Workflow of our mRNA dendritic cell mRNA vaccine service
Creative Biogene is passionate about strong customer orientation and high-quality service. With advanced instruments and professional scientists in the field of mRNA-based drug R&D, we have established a series of efficient integrated solutions to facilitate and accelerate our customers' mRNA vaccine development. Please don't hesitate to contact us for more information.
- Benteyn, D., et al, (2015). "mRNA-based dendritic cell vaccines." Expert review of vaccines, 14(2), 161-176.
- Zeng, C., et al. (2020). "Formulation and Delivery Technologies for mRNA Vaccines." 1-40.